Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12835706 | 0.91 | CTSS (0.56) | CTSKCTSSFNTAFNTBMEN1 | |
| SCHEMBL29558421 | 0.91 | CTSS (0.56) | CTSKCTSSFNTAFNTBMEN1 | |
| SCHEMBL11494122 | 0.88 | CTSS (0.53) | CTSKCTSSFNTAFNTBMEN1 | |
| SCHEMBL11494115 | 0.88 | CTSS (0.53) | CTSKCTSSFNTAFNTBMEN1 | |
| SCHEMBL29454915 | 0.86 | CTSK (0.50) | CTSKCTSSCYP2D6MEN1KMT2A | |
| SCHEMBL10308623 | 0.86 | CTSK (0.46) | CTSKCTSSFNTAFNTBMEN1 | |
| SCHEMBL617475 | 0.86 | PPARA (0.48) | CTSKCTSSCYP2D6MEN1KMT2A | |
| SCHEMBL617476 | 0.86 | PPARA (0.48) | CTSKCTSSCYP2D6MEN1KMT2A | |
| SCHEMBL2564729 | 0.86 | PPARA (0.48) | CTSKCTSSCYP2D6MEN1KMT2A | |
| SCHEMBL22500526 | 0.83 | CTSK (0.59) | CTSKCTSSFNTAFNTBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240247030-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | JPMORGAN CHASE BANK, N.A. | 2024-07-25 | — | — | US | disclosed |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-3900742-B1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEAGEN INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4074328-A1 | INTERMEDIATES OF CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | Seagen Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3383420-B1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247030-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | CD47, CD44, MSR1 | CTSK 3383/4885CTSS 3176/4885FNTA 2535/4885 |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CTSK 1371/4885CTSS 2029/4885FNTA 1649/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CTSK 1371/4885CTSS 2029/4885FNTA 1649/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | CTSK 1371/4885CTSS 2029/4885FNTA 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.